Article abstract-Background: Miller Fisher syndrome (MFS), a variant of the Guillain-Barré syndrome, is associated with the presence of neuromuscular blocking antibodies, some of which may be directed at the ganglioside GQ1b.
Miller Fisher syndrome (MFS) is characterized by the triad of gait ataxia, external ophthalmoplegia, and areflexia. 1 As a variant of the Guillain-Barré syndrome (GBS), MFS is thought to be an immunopathologic disorder of the peripheral nervous system. Immunoglobulin (Ig) G autoantibodies directed at the ganglioside GQ1b are found in the acute phase sera of more than 90% of patients with MFS. [2] [3] [4] Gangliosides are present in high concentrations in peripheral nerve axons and myelin, and several studies indicated that different gangliosides (e.g., GM1) are present at nodes of Ranvier and at neuromuscular junctions. 5 The distal motor nerve terminal lacks the blood-nerve barrier, making it accessible for circulating antibodies and a suitable site to investigate the functional effects of serum-antibodies experimentally.
There is evidence that MFS sera block neuromuscular transmission in the mouse hemidiaphragm. [6] [7] [8] [9] Using intracellular microelectrode techniques, a marked increase in spontaneous release (i.e., miniature endplate potential frequency) after application of MFS sera, followed by inexcitability of the muscle upon phrenic nerve stimulation has been demonstrated. 6, 9 In that study, the effects depended entirely on the presence of complement, 9 and miniature endplate potential (MEPP) amplitudes appeared unchanged. 6, 9 With a perfused macro-patch clamp electrode, we have previously shown that the purified IgG fraction and fractions containing monovalent, antigen-binding (Fab) fragments of two patients with MFS rapidly and reversibly depressed evoked quantal release, whereas the IgM fractions had no effect. 7, 8 Furthermore, MFS-IgG reduced the amplitude of single quanta, indicating a superimposed postsynaptic effect. 8 In the current study, we addressed the postsynaptic side more directly by examining the effect of MFS-IgG on acetylcholine (Ach)-induced currents in mouse myotubes using outside-out patch clamp analysis. Using the perfused macro-patch clamp electrode we investigated whether the presence of blocking antibodies is a more general feature in patients with MFS, and whether it is disease-related.
Materials and methods. Patient sera and purified
IgG. Eleven patients with MFS were defined according to standard clinical and electrophysiologic criteria. 10, 11 Six men and five women between 23 and 71 years of age were included. One patient had a preceding gastrointestinal infection and six patients had an upper respiratory tract infection. Five patients (Patients 1, 3, 6, 7, 8) showed bulbar involvement in addition to ophthalmoplegia but no generalized muscle weakness. Four patients (Patients 2, 4, 9, 10) presented with ophthalmoplegia and moderate generalized weakness (Hughes grade 1 or 2). 12 Two patients (Patients 5 and 11) developed severe generalized muscle weakness (Hughes grade 4 to 5) after initially pure extraocular involvement. 13 In four patients (Patients 5, 6, 7, 8) , amplitudes of compound muscle action potentials were moderately reduced around the time of serum collection. Six patients were treated with plasma exchange (Patients 1, 4, 5, 9, 10, 11), and two were treated with IV IgG (Patients 7 and 8). Except for Patient 8, who died of septicemia, all patients eventually recovered to normal or almost normal neurologic function (seven patients recovered within 4 weeks).
Early serum samples were obtained within 2 weeks after onset of symptoms. Plasma filtrate was obtained during therapeutic plasmapheresis; for patch clamp investigations, the filtrate of the first exchange was chosen (i.e., before any additional therapies). Convalescent serum samples were obtained in three patients after full recovery at least 6 months after onset of disease. Serum samples were stored for up to 1 week at 4°C and then at Ϫ20°C until used. Immunoglobulins were purified by affinity chromatography as previously described. 7 Lyophilized IgG was dissolved in the assay buffer just prior to use.
For control experiments (control IgG), a commercial polyclonal IgG preparation (Venimmun, Aventis-Behring, Marburg, Germany) was used. Additional control serum samples from patients with cervical disk herniation, and with Borrelia infection and polyradiculitis were investigated by outside-out patch clamp analysis.
Anti-GQ1b antibodies were partly purified by affinity chromatography from one serum (Patient 11). It contained high-titer anti-GQ1b (1:3,200 by ELISA and 1:32,000 by overlay high-performance thin-layer chromatography [HPTLC]), and borderline low titers of anti-GD3 (1/4,000 by overlay HPTLC) and anti-GD1b (1/500 by overlay HPTLC). In order to minimize contaminations with other immunoglobulins and complement components, the purified IgG fraction (Mab TRAp GII kit, Pharmacia, Sweden) from this patient's serum was used for further affinity chromatography. Octyl-Sepharose 4B (Pharmacia, Sweden) was used as a gel for binding the purified antigen GQ1b (Sigma Chemical Corp., St. Louis, MO) as described. 14 The gel was washed several times with a solution of 1:1 methanol/H2O containing 0.1 M KCl (solution 1) and equilibrated with the same solution. Partly purified GQ1b (0.4 mg) was dissolved in 1.6 mL solution 1 and warmed in a water bath at 70°C for 30 minutes. Then, 1.5 mL gel was conjugated with the suspension of GQ1b and packed in a column for affinity chromatography. The column was washed with phosphate-buffered saline (PBS) at pH 7.4, and the IgG fraction of patient's serum was added. The column was again washed with PBS to remove unbound antibodies. For desorbing the antibodies bound on the gel, the column was eluted at room temperature with 3 M NaSCN and the eluate was collected in 1 mL fractions. Then, the mean absorbance of each sample was read at 280 nm wavelength by spectrophotometry. The fractions containing anti-GQ1b IgG were pooled, dialyzed against PBS, and concentrated. Using this procedure, we were able to purify only a small fraction (Ͻ10%) of the anti-GQ1b IgG present in the original patient's serum; the majority portion was eluted with the serum in the first wash. It cannot be excluded that this fraction contained antibodies reacting with other ganglioside epitopes.
Anti-Ach receptor (AchR)-antibodies were determined by a radioimmunoassay as described. 15 Antibodies to GQ1b and GM1 were measured by ELISA and by dot-blot assays as described. 16, 17 Purified IgG fractions were also examined by HPTLC as described. 4 Recording techniques and statistics. Perfused macropatch clamp technique on mouse hemidiaphragm. Experiments were performed on hemidiaphragms of male BALB/c mice that were at least 16 weeks old, at 20 Ϯ 0.5°C as described. 8 Endplate currents were recorded by means of a perfused macro-patch clamp electrode as described in detail elsewhere. 18, 19 Statistical analysis was done with a commercial computer program (Origin, Microcal Software, Northhampton, MA). Statistical p values were calculated using the Student's t-test for grouped data.
At the beginning of each experiment, the electrode was perfused with control solution, the position of the electrode was optimized, and the quantal excitatory postsynaptic currents (qEPSC) were recorded and counted. When recording conditions were stable, diluted sera (1:4) or immunoglobulins dissolved in the N-2-hydroxyethylpiperazine-N-2-ethanesulfonic (HEPES) buffer at a concentration of about 4 to 6 mg/mL (except for the partly purified anti-GQ1b and depleted IgG fractions) were added to the perfusate of the electrode while recording from a selected nerve terminal stimulated by a fixed depolarizing current pulse. The quantal content "m" is given as mean Ϯ SD from the results of at least three independent experiments.
Outside-out patch recordings on cultured mouse myotubes. The patch clamp experiments were performed on cultured mouse myotubes prepared as previously de- scribed. 20 The embryonic-type of nicotinic AchR (nAchR)-channel, made up of ␣2␤␥␦ subunits, is found exclusively. 20 Patch clamp experiments were performed in the outsideout configuration using standard protocols 21 as described in detail elsewhere. 22 For application of Ach to outside-out patches, we used a piezo-driven tool for ultrafast solution exchange. 23 In our set-up, the solution exchange typically took 90 s. 24 In the present study we applied short Ach-pulses of 20 ms duration with a frequency of 0.25 Hz. For experiments with MFS-IgG, the respective IgG concentration was applied via the background flow of the application system as previously described. 22 The solution exchange of the background system took around 100 ms.
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Results. Effects of MFS sera or IgG on presynaptic transmitter release. Application of serum or IgG from all 11 MFS patients significantly reduced quantal content, whereas control IgG were without blocking effect (figure 1). The blockade by the MFS-IgG or MFS-sera could be fully reversed by washing with control solution in four of 11 patients, and partly in six of 11 patients. In only one serum (Patient 3), the blockade was not reversible. The final effects of each serum or IgG studied are shown in table 1 .
In every patient, the blockade could be overcome by stronger depolarization of the nerve terminal 8 (data not shown), confirming the presynaptic nature of the blockade and excluding technical malfunction as a reason for the observed decrease in quantal content.
In addition, we studied serum, purified IgG, and the IgG fraction enriched for anti-GQ1b antibodies from the same patient (Patient 11) with a high titer of anti-GQ1b antibodies (1:3,200 in serum) separately. All fractions revealed blocking properties with a significant reduction in evoked quantal release. The mean reduction in quantal content m relative to the control for whole serum (1:4 diluted) was 0.26 Ϯ 0.04; and for purified MFS-IgG at a concentration of 2.6 mg/mL, it was 0.22 Ϯ 0.03. The IgG fraction enriched for anti-GQ1b antibodies had a much lower IgG concentration of 0.036 mg/mL, and induced a tenfold stronger reduction in quantal content (m ϭ 0.029 Ϯ 0.01). In contrast, the IgG fraction partially depleted from anti-GQ1b antibodies (residual anti-GQ1b titer 1:400) was less effective in blocking evoked quantal release (m ϭ 0.43 Ϯ 0.15) at an equivalent IgG concentration.
Effect of MFS sera or IgG on postsynaptic currents.
Macro-patch clamp analysis. To investigate the postsynaptic action of the MFS sera amplitudes of (qEPSC) were analysed. Figure 2 depicts amplitude distributions before, during, and after application of the MFS-IgG of Patient 11. Under control conditions (see figure 2A) , the histogram revealed two peaks indicating release of single and double quanta. For single quanta, the mean amplitude was Ϫ1648 pA. Even the smallest amplitudes were well above the noise level of the recording system. In the presence of the MFS-IgG (see figure 2B ), the mean amplitude was markedly reduced when compared to control. Due to the presynaptic blockade, only single quanta were released and the histogram showed only one peak with a mean amplitude of Ϫ1200 pA. After wash-out, mean amplitude and distribution were almost identical to control conditions (see figure 2C). In the presence of the MFS-serum, amplitudes of single quanta were reduced in 10 out of 11 patients; in seven of these 10 patients, the amplitudes recovered completely after wash-out (table 2) . Outside-out patch clamp analysis. To study the postsynaptic effects of the MFS-IgG avoiding interference with the presynaptic depression of release, we investigated the MFS-IgG of five patients by patch clamp technique in the outside-out configuration on mouse myotubes. The peak current amplitude elicited by a saturating concentration of 1.0 mM Ach was evaluated before, during, and after Effect of convalescent serum on quantal content and qEPSC. To further examine the pathogenic relevance of the observed blocking effects, sera from the acute phase of disease and sera obtained after full recovery were investigated at the same nerve terminal (figure 4). After application of the MFS-IgG from Patient 1 during the height of the illness, quantal release was almost completely blocked within 5 minutes. Returning to control solution, quantal content recovered fully within 7 minutes. During superfusion with the convalescent serum, quantal content remained stable at the same level for more than 30 minutes. Neither the amplitude of single quanta nor the decay time constant was affected by the convalescent serum, indicating that the original postsynaptic effects had also subsided. The experiment shown in figure 4 is representative for nine experiments of this type with the sera of three different patients (see tables 1 and 2).
Serum antibodies. Specific reactivity to GQ1b ganglioside was found at high titer in ELISA and dot-blot assays in nine out of 11 patients in the IgG, but not in the IgM, fraction. No IgM or IgG binding to GM1 was detected. In two patients (Patients 9 and 10), no anti-GQ1b or anti- Amplitude of single quanta (mean Ϯ SD; see figure 2 ) before, during, and after application of the MFS serum; the p value for the reduction in amplitude after application of early MFS immunoglobulin G was p Ͻ 0.001 when compared to the control group.
Figure 2. Amplitude distribution of quantal excitatory postsynaptic currents (qEPSC) before, during, and after application of the Miller Fisher syndrome (MFS) immunoglobulin G (IgG
ND ϭ not done.
GM1 antibodies could be detected by standard ELISA. In patients with follow-up serology 2 to 6 months later, specific IgG binding to these gangliosides had disappeared. None of the patients' sera showed elevated titers (Ͼ0.4 nmol/L) of antibodies to nAchR in the standard immunoprecipitation assay.
Discussion. Our study shows that neuromuscular blocking antibodies are common in MFS. Postsynaptically, the antibodies directly interfere with Ach receptor channels. All sera lost pre-and postsynaptic blocking properties after complete clinical recovery.
Presynaptic blockade by MFS-IgG.
The presynaptic depression of evoked quantal release may be explained by an interference of the MFS-IgG with voltage-gated calcium channels 8 (not unlike the action of Lambert-Eaton myasthenic syndrome [LEMS]-IgG 26, 27 ), or may indicate changes within the release machinery similar to the action of botulinum toxin. 28 We found a slight increase in late releases which may reflect increase in spontaneous release after application of MFS-IgG. 8 We did not observe a profound increase in spontaneous release followed by complete inexcitability of the nerve terminal as described after bath incubation of the whole nerve muscle preparation with MFS serum together with active complement. 6, 9 The fact that we stimulate and treat only a small patch of the synaptic region, 19 and that the Values are mean Ϯ SD (number of patches studied).
*Peak current amplitudes were normalized to the current elicited by 1.0 mM ACh when no serum or IgG was present.
IgG ϭ immunoglobulin G. combined pre-and postsynaptic blockade is seen without addition of active complement, may account for some basic differences in comparison to the results published on bath application with long incubation times and intracellular recordings. 9, 29 Because of the complement independence and the reversibility of the blockade, our data are best explained by an immunopharmacologic effect of IgG antibodies. One hypothesis to reconcile both these observations would be that these are different yet complementary functions of antibodies, not unlike the situation in myasthenia gravis where both complement-dependent alterations and direct immunopharmacologic blockade of the AchR are operative. 30, 31 Postsynaptic blockade. The additional action of the MFS-IgG on postsynaptic nAchR channels first observed with the macro-patch clamp technique was corroborated and now shown to be an independent effect by single channel measurements. Our data indicate binding of the MFS-IgG to the nonliganded state of the AchR-channel, as described for myasthenic antibodies. 22, 31 Because the exact amount of specific activity in the IgG-fraction is unknown, the rate constants of binding and unbinding were not calculated. The time course of the blockade by MFSIgG seems to be slightly faster than for purified IgG from patients with myasthenia gravis. 22 Despite the functional evidence of MFS antibodies acting at the nAchR, binding of the MFS-IgG was not found by the diagnostic immunoprecipitation assay. This is not unexpected, since antibodies binding at or near the binding site of nAchR channels are usually not detected by the diagnostic immunoprecipitation assay. 15, 32 When comparing the observations obtained by the macro-patch clamp technique with those obtained by the outside-out patch clamp method, one has to take into account that the AchR may not be as easily accessible to the antibody in an intact nerve muscle preparation as it is in myotubes expressing nAchR channels. This may account for quantitative differences in the dose-response relationship. Altogether, the data obtained by the two independent methods are in good agreement, clearly indicating a postsynaptic effect of MFS-IgG. The results for MFSIgG resemble our previous findings with IgG fractions from patients with GBS, yet with some remarkable differences. 19 In our experiments with GBS sera, the postsynaptic currents were affected in only four out of 10 patients. Furthermore, the time course of blockade with GBS-IgG tended to be slower, and the blockade induced by GBS-filtrate could not be reversed after prolonged incubation times. It is conceivable that different antiganglioside antibodies show different modes of binding and neuromuscular blockade.
The possible role of anti-ganglioside antibodies. From the present data, there is no hint as to whether the blocking antibodies are directed against one homologous epitope expressed both pre-and postsynaptically, or whether this combined blocking action is due to a polyclonal immune response with multiple antibodies directed at different epitopes. A number of different studies have suggested that GQ1b is the candidate antigen in MFS, 9, 29, [33] [34] [35] but the putative pathogenic role of anti-GQ1b antibodies still remains speculative because direct proof by experimental data is not yet available. Our investigations using an immunoglobulin fraction enriched for anti-GQ1b antibodies also does not unequivocally prove the pathogenic relevance of GQ1b gangliosides, since crossreactivity with other ganglioside epitopes cannot be ruled out. The fact that anti-GQ1b antibodies were no longer detectable after recovery, along with the loss of blocking activity, is suggestive but not conclusive evidence. Future studies should make use of monoclonal IgG antibodies binding exclusively to GQ1b.
In two out of 11 patients, we did not find detectable anti-GQ1b antibodies by ELISA, although their sera reduced evoked quantal release to the same extent as anti-GQ1b positive sera. We assume that our detection system (ELISA and dot-blot) may have failed to detect low titer activity, as has been described earlier. 36, 37 Specifically, our assay uses bovine brain gangliosides, and therefore antibodies to specific peripheral nerve gangliosides may not be detected. Indeed, for serum anti-GM1 antibodies, different binding affinities to gangliosides derived from peripheral and central nervous systems have been described in a patient with GBS. 38, 39 Alternatively, the antibodies may not have been detected by ELISA due to conformational differences, although they may be functionally active. This would resemble findings in some patients with seronegative myasthenia gravis. 22 Finally, it cannot be excluded that functionally relevant antibodies react with glycoconjugates other than GQ1b.
Clinical implications. A combined pre-and postsynaptic defect may add up to compromise the safety margin of neuromuscular transmission. Muscles with the lowest safety margin, such as the extraocular muscles, could be preferentially involved. 40 Indeed, a clinical electrophysiologic case study suggests that motor nerve terminal block may induce muscle weakness in MFS. 41 In MFS patients, however, we did not observe abnormal fatigability and fluctuation of muscle weakness as one might expect in assuming a myasthenia-like action of blocking antibodies. This may be due to the combination of a pre-and postsynaptic blockade 42, 43 whereby the postsynaptic transmission defect cannot be partially compensated for by presynaptic increase in quantal content. 44, 45 Interestingly, the clinical pattern of primarily affecting extraocular muscle and cranial nerves, and the mode of paralysis in MFS are very similar to those found with botulism, a toxin-induced disorder of impaired presynaptic transmitter release. Evidence for a pathogenic role of T cells in chronic inflammatory demyelinating polyneuropathy (CIDP) includes an increased frequency of circulating activated peripheral T cells, 1,2 and elevated serum levels of interleukine-2 (Il-2) and soluble Il-2 receptors. 3 In both CIDP and vasculitic neuropathy, increased numbers of T cells in the sural nerve biopsy specimens may indicate a role for T cells in the disease mechanism. [4] [5] [6] It is currently not clear whether sural nerve T cells, their numbers increased or not, are disease-specific autoreactive T cells, or whether these are attracted nonspecifically to the peripheral nervous tissue.
Analysis of T-cell receptors (TCR) in affected tissue may show 1) a broad TCR repertoire without V␤ family overrepresentation (similar to that found in peripheral blood or normal lymph nodes), indicating that the T cells have been attracted nonspecifically by a proinflammatory environment; 2) a restricted TCR repertoire with V␤ family overrepresentation but without evidence of clonal expansion, indicating that there may be a superantigen-driven T cell expansion; or 3) a restricted TCR repertoire with V␤ family overrepresentation and clonal expansion, indicating that the T cells have been stimulated by specific antigens. 7 Patterns of restricted TCR V␤ gene expression have been described in studies of multiple sclerosis, 8 inflammatory myopathies, 9-16 psoriasis, 17 and Sjögren's syndrome 18 ; whereas other studies of MS, 19 rheumatoid arthritis, 20 and anti-Hu paraneoplastic encephalomyelitis/sensory neuronopathy 7 have indicated a more heterogeneous TCR V␤ utilization of T cells in situ.
